BVF PARTNERS L P/IL - 17 Feb 2026 Form 3 Insider Report for IMMUNIC, INC. (IMUX)

Reporting relationship
Director, Other*
Issuer ticker
IMUX
Reported as of
17 Feb 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
27 Feb 2026, 17:03:09 UTC
Prior SEC filing
30 Jan 2026
Next SEC filing
02 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President

Key filing fact

BVF PARTNERS L P/IL filed Form 3 for IMMUNIC, INC. (IMUX) on 27 Feb 2026.

Key facts

  • This page summarizes BVF PARTNERS L P/IL's Form 3 filing for IMMUNIC, INC. (IMUX).
  • 0 reported transactions and 12 derivative rows are listed below.
  • Accepted by SEC: 27 Feb 2026, 17:03.

Change

  • Previous filing in this sequence was filed on 30 Jan 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (10)

CIK 0001055947 Primary reporting owner

BVF PARTNERS L P/IL

Relationship
Director, Other*
Address
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature
BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date
27 Feb 2026
CIK 0000918923

BIOTECHNOLOGY VALUE FUND L P

Relationship
Director, Other*
Address
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature
Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date
27 Feb 2026
CIK 0001803805

BVF I GP LLC

Relationship
Director, Other*
Address
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature
BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date
27 Feb 2026
CIK 0001102444

BIOTECHNOLOGY VALUE FUND II LP

Relationship
Director, Other*
Address
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature
Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date
27 Feb 2026
CIK 0001803806

BVF II GP LLC

Relationship
Director, Other*
Address
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature
BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date
27 Feb 2026
CIK 0001660683

Biotechnology Value Trading Fund OS LP

Relationship
Director, Other*
Address
P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS
Signature
BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date
27 Feb 2026
CIK 0001660684

BVF Partners OS Ltd.

Relationship
Director, Other*
Address
P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS
Signature
Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Signature date
27 Feb 2026
CIK 0001803809

BVF GP HOLDINGS LLC

Relationship
Director, Other*
Address
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature
BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer
Signature date
27 Feb 2026
CIK 0001056807

BVF INC/IL

Relationship
Director, Other*
Address
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature
BVF Inc., By: /s/ Mark N. Lampert, President
Signature date
27 Feb 2026
CIK 0001233840

LAMPERT MARK N

Relationship
Director, Other*
Address
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO
Signature
/s/ Mark N. Lampert
Signature date
27 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMUX holding

Common Stock, $0.0001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
4,135,956
Date
17 Feb 2026
Ownership
Direct
Footnotes
F1, F2
IMUX holding

Common Stock, $0.0001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,027,105
Date
17 Feb 2026
Ownership
Direct
Footnotes
F1, F3
IMUX holding

Common Stock, $0.0001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
427,629
Date
17 Feb 2026
Ownership
Direct
Footnotes
F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
4,496,000
Exercise price
Footnotes
F1, F2, F5
IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
3,514,428
Exercise price
Footnotes
F1, F3, F5
IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
444,452
Exercise price
Footnotes
F1, F4, F5
IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
6,817,521
Exercise price
Footnotes
F1, F2, F6
IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
5,278,894
Exercise price
Footnotes
F1, F3, F6
IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
912,813
Exercise price
Footnotes
F1, F4, F6
IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
28,797,932
Exercise price
Footnotes
F1, F2, F7
IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
20,525,707
Exercise price
Footnotes
F1, F3, F7
IMUX holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
3,202,262
Exercise price
Footnotes
F1, F4, F7
IMUX holding Derivative

Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
28,797,932
Exercise price
Footnotes
F1, F2, F8, F9
IMUX holding Derivative

Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
20,525,707
Exercise price
Footnotes
F1, F3, F8, F9
IMUX holding Derivative

Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock, $0.0001 par value
Underlying amount
3,202,262
Exercise price
Footnotes
F1, F4, F8, F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

This Form 3 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

Footnote F2

Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general parter of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

Footnote F3

Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

Footnote F4

Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

Footnote F5

The Reporting Persons hold certain Pre-Funded Warrants (the "2024 Pre-Funded Warrants") exercisable for an aggregate of 8,580,151 shares of Common Stock. The 2024 Pre-Funded Warrants do not expire and have an exercise price of $0.0001 per share. The 2024 Pre-Funded Warrants are exercisable immediately, except that the 2024 Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.9% of the shares of Common Stock outstanding.

Footnote F6

The Reporting Persons hold certain Pre-Funded Warrants (the "2025 Pre-Funded Warrants") exercisable for an aggregate of 13,335,000 shares of Common Stock. The 2025 Pre-Funded Warrants do not expire and have an exercise price of $0.0001 per share. The 2025 Pre-Funded Warrants are exercisable immediately, except that the 2025 Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.

Footnote F7

The Reporting Persons hold certain Pre-Funded Warrants (the "2026 Pre-Funded Warrants") exercisable for an aggregate of 53,257,500 shares of Common Stock. The 2026 Pre-Funded Warrants do not expire and have an exercise price of $0.0001 per share. The 2026 Pre-Funded Warrants are exercisable immediately, except that the 2026 Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.

Footnote F8

The Reporting Persons hold certain Warrants (the "Common Warrants") exercisable for an aggregate of 53,257,500 shares of Common Stock. The Common Warrants are exercisable at a price $0.873220 per share of Common Stock following the completion of the Issuer's reverse stock split until the earlier of (i) 30 trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 ENSURE trials (for the avoidance of doubt, the later date of the initial public announcement of topline data from ENSURE-1 or ENSURE-2, if announced separately) (the "Topline Data Announcement"), (ii) immediately upon the exercise of the 2026 Pre-Funded Warrants if such exercise of 2026 Pre-Funded Warrants is prior to the Topline Data Announcement, provided that if the 2026 Pre-Funded Warrant is not exercised in full, the Common Warrant expires proportionally only to the extent the 2026 Pre-Funded Warrant is exercised, and (iii) February 17, 2031.

Footnote F9

The Common Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.

SEC remarks

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a Principal of Partners, R. Thorvald Nagel, serving on the Board of Directors of the Issuer, and his agreement to transfer to Partners the economic benefit, if any, received upon the sale of any securities of the Issuer he receives in his capacity as a director of the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .